Charge-to-alanine mutagenesis of dengue virus type 4 (DEN4) NS5 gene generated a collection of attenuating mutations for potential use in a recombinant live attenuated DEN vaccine. Codons for 80 contiguous pairs of charged amino acids in NS5 were individually mutagenized to create uncharged pairs of alanine residues, and 32 recombinant mutant viruses were recovered from the 80 full-length mutant DEN4 cDNA constructs. These mutant viruses were tested for temperature-sensitive (ts) replication in both Vero cells and HuH-7 human hepatoma cells. Of the 32 mutants, 13 were temperature sensitive (ts) in both cell lines, 11 were not ts in either cell line, and 8 exhibited a host range (tshr) phenotype. One tshr mutant was ts only in Vero cells, and seven were ts only in HuH-7 cells. Nineteen of the 32 mutants were 10-fold or more restricted in replication in the brains of suckling mice compared to that of wild-type DEN4, and three mutants were approximately 10,000-fold restricted in replication. The level of temperature sensitivity of replication in vitro did not correlate with attenuation in vivo. A virus bearing two pairs of charge-to-alanine mutations was constructed and demonstrated increased temperature sensitivity and attenuation relative to either parent virus. This large set of charge-to-alanine mutations specifying a wide range of attenuation for mouse brain should prove useful in fine-tuning recombinant live attenuated DEN vaccines.Dengue virus (DEN) (genus Flavivirus, family Flaviviridae) is a single-stranded, positive-sense RNA virus with a 10.6-kb genome. The genome organization of DEN viruses is 5Ј-UTR-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-UTR-3Ј (UTR, untranslated region; C, capsid; prM, membrane precursor; E, envelope; NS, nonstructural) (6, 34). DEN is comprised of four serotypes, each of which is capable of causing dengue fever (DF) and its more-severe variants, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DEN is transmitted by mosquitoes of the genus Aedes. In the past few decades, unregulated urbanization, modern patterns of travel, cessation of vector control, and other factors have led to a rapid expansion in the geographic range of all four serotypes and the cocirculation of two or more serotypes in many areas (15). Concurrently, the number of reported cases of DHF and DSS has risen dramatically. It is estimated that 50 to 100 million cases of DF and several hundred thousand cases of DHF and DSS occur annually (14, 15). Unfortunately, there is neither a licensed vaccine nor an effective antiviral therapy for the control of DEN infection. Because progression to DHF or DSS is more likely during secondary infection (27, 38), an acceptable dengue vaccine must confer immunity to all four serotypes. To date, attempts to develop tetravalent live-attenuated vaccines via cell culture passage have resulted in uneven attenuation, such that effective immunity is not induced to all four serotypes, and the most immunogenic viruses also tend to be reactogenic (4, 18).We are developing live ...